Total Payments
$1,310
2024 Payments
$72.57
Companies
11
Transactions
14
Medicare Patients
2,018
Medicare Billing
$232,315
Payment Breakdown by Category
Research$549.20 (41.9%)
Consulting$350.00 (26.7%)
Food & Beverage$236.42 (18.0%)
Education$174.27 (13.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $549.20 | 1 | 41.9% |
| Consulting Fee | $350.00 | 3 | 26.7% |
| Food and Beverage | $236.42 | 5 | 18.0% |
| Education | $174.27 | 5 | 13.3% |
Payments by Type
General
$760.69
13 transactions
Research
$549.20
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $549.20 | 1 | $0 (2021) |
| COMSORT, Inc | $350.00 | 3 | $0 (2019) |
| Astellas Pharma US Inc | $99.00 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $74.96 | 1 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $72.57 | 1 | $0 (2024) |
| Intuitive Surgical, Inc. | $51.34 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $34.09 | 1 | $0 (2022) |
| PFIZER INC. | $29.26 | 2 | $0 (2019) |
| Genentech, Inc. | $21.92 | 1 | $0 (2018) |
| Pharmacyclics LLC, An AbbVie Company | $15.63 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72.57 | 1 | Janssen Scientific Affairs, LLC ($72.57) |
| 2022 | $85.43 | 2 | Intuitive Surgical, Inc. ($51.34) |
| 2021 | $576.75 | 3 | Eli Lilly and Company ($549.20) |
| 2019 | $189.59 | 3 | COMSORT, Inc ($100.00) |
| 2018 | $186.55 | 3 | COMSORT, Inc ($150.00) |
| 2017 | $199.00 | 2 | COMSORT, Inc ($100.00) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $72.57 | General |
| 12/09/2022 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Education | In-kind items and services | $34.09 | General |
| Category: Oncology | ||||||
| 08/09/2022 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $51.34 | General |
| Category: SURGERY | ||||||
| 07/27/2021 | Eli Lilly and Company | — | — | In-kind items and services | $549.20 | Research |
| Study: EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | ||||||
| 07/01/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/03/2019 | COMSORT, Inc | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $74.96 | General |
| Category: Oncology | ||||||
| 05/29/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2018 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2018 | COMSORT, Inc | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2018 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: BioOncology | ||||||
| 04/06/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 03/28/2017 | COMSORT, Inc | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $100.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $549.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 450 | 667 | $167,994 | $54,964 |
| 2022 | 9 | 571 | 871 | $203,619 | $69,335 |
| 2021 | 11 | 674 | 970 | $233,763 | $77,076 |
| 2020 | 10 | 323 | 451 | $107,243 | $30,939 |
Total Patients
2,018
Total Services
2,959
Medicare Billing
$232,315
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 171 | 339 | $72,844 | $25,411 | 34.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 102 | 139 | $48,120 | $15,811 | 32.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $15,996 | $4,974 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 86 | 94 | $14,932 | $3,961 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 27 | 27 | $9,184 | $2,630 | 28.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $5,062 | $1,462 | 28.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 18 | $1,857 | $715.68 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 179 | 401 | $86,167 | $30,252 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 62 | 87 | $26,453 | $10,145 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 156 | 187 | $26,988 | $9,002 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 49 | 49 | $21,772 | $6,992 | 32.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 36 | 36 | $12,245 | $3,655 | 29.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 20 | $10,621 | $3,217 | 30.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 21 | $7,593 | $2,297 | 30.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 32 | $6,073 | $1,854 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 16 | $3,438 | $1,230 | 35.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 16 | 22 | $2,269 | $691.01 | 30.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 195 | 437 | $97,875 | $33,819 | 34.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 76 | 76 | $35,206 | $11,054 | 31.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 161 | 191 | $28,169 | $9,550 | 33.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 62 | 62 | $21,647 | $6,358 | 29.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 47 | 56 | $16,965 | $6,354 | 37.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $7,966 | $2,305 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 27 | $7,385 | $2,291 | 31.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 19 | $4,733 | $1,220 | 25.8% |
About Dr. Thomas Openshaw, MD
Dr. Thomas Openshaw, MD is a Hematology & Oncology healthcare provider based in Brewer, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588695811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Openshaw, MD has received a total of $1,310 in payments from pharmaceutical and medical device companies, with $72.57 received in 2024. These payments were reported across 14 transactions from 11 companies. The most common payment nature is "" ($549.20).
As a Medicare-enrolled provider, Openshaw has provided services to 2,018 Medicare beneficiaries, totaling 2,959 services with total Medicare billing of $232,315. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brewer, ME
- Active Since 07/05/2006
- Last Updated 11/23/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1588695811
Products in Payments
- KEYTRUDA (Biological) $350.00
- TAGRISSO (Drug) $74.96
- Da Vinci Surgical System (Device) $51.34
- SPRYCEL (Drug) $34.09
- XTANDI (Drug) $29.26
- TECENTRIQ (Biological) $21.92
- IMBRUVICA (Drug) $15.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brewer
Dr. Philip Brooks, Md, MD
Hematology & Oncology — Payments: $5,739
Hematology & Oncology $5,739
Shruti Bhandari, M.d, M.D
Hematology & Oncology — Payments: $4,837
Hematology & Oncology $4,837
Yelena Patsiornik, Md, MD
Hematology & Oncology — Payments: $1,999
Hematology & Oncology $1,999
Dr. Sigrid Berg, Md, MD
Hematology & Oncology — Payments: $221.02
Hematology & Oncology $221.02
Jens Rueter, Md, MD
Hematology & Oncology — Payments: $218.42
Hematology & Oncology $218.42
Audrey Garrett, Md, MD
Hematology & Oncology — Payments: $173.66
Hematology & Oncology $173.66